drugset / Trial / NCT06818643

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643

Phase 1/2 Recruiting 270 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Timeline

Start
2025-03-25
Primary completion
2028-10-25
Completion
2031-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-3120 Unknown Intravenous

Indications